Cryo Cell International Inc 's

• CCEL's Stock Performance relative to its Competitors

Cellectis S a Share Performance -3.69% This Quarter

Cellectis S a Profile Cellectis S is a biotechnology company that operates using a business model focused on developing and commercializing gene editing technologies. They utilize a proprietary platform called TALEN® to modify genes for various applications in agriculture, healthcare, and biomanufacturing. By providing innovative solutions through gene editing, Cellectis aims to address critical challenges in these industries and create value for their customers and stakeholders. More about Cellectis S a 's Market Share

Kalaris Therapeutics Inc Share Performance -25.05% This Quarter

Kalaris Therapeutics Inc Profile The company develops and commercializes treatments for retinal diseases using the anti-VEGF drug TH103. More about Kalaris Therapeutics Inc 's Market Share

Kyntra Bio Inc Share Performance +13.19% This Quarter

Kyntra Bio Inc Profile The company conducts preclinical development and clinical trials for its product candidates. More about Kyntra Bio Inc 's Market Share

Vericel Corporation Share Performance +13.73% This Year

Vericel Corporation Profile Vericel Corporation's business model revolves around the development and commercialization of innovative cellular therapies for the treatment of severe diseases and conditions. More about Vericel Corporation's Market Share

Sources: Cryo cell International Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, July 7, 2026 3:09 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cryo cell International Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.